Wellbutrin

(Bupropion)

ApprovedSmall molecule

Bupropion is used to treat depression by helping to improve mood and motivation. It's also used to help people quit smoking by reducing cravings and withdrawal symptoms.[2] Wellbutrin is currently approved and in use across 30 indications[4].[1]

Wellbutrin is one of 670 small molecule programs targeting Smoking Cessation. It is currently in Approved.

Indications

172

Total Trials

Active Trials

669

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Smoking CessationCompleted

Pulmonary TuberculosisActive, not recruiting

Smoking BehaviorActive, not recruiting

ObesityActive, not recruiting

Pathological GamblingActive, not recruiting

Prostate CancerApproved

Bipolar DisorderApproved

Alcohol AbuseApproved

Drug DependenceApproved

Chronic Lymphocytic LeukemiaApproved

Smoking CessationApproved

Completed

Pulmonary TuberculosisPreclinical

Active, not recruiting

Smoking BehaviorPreclinical

Active, not recruiting

ObesityApproved

Active, not recruiting

Pathological GamblingPreclinical

Active, not recruiting

Prostate CancerApproved

Approved

Bipolar DisorderApproved

Approved

Alcohol AbuseApproved

Approved

Drug DependenceApproved

Approved

Chronic Lymphocytic LeukemiaApproved

Approved

Showing 10 of 30 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Nubain

AAultman Health Foundation

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 8

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 9

Gadolinium-Chelate

MM.D. Anderson Cancer Center

Preclinical

1 10

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Chronic Kidney Diseases

NCT04422652

Phase 3Recruiting

Treatment

NCT05732272

Phase 3Active, not recruiting

Methamphetamine Dependence

NCT06233799

Q4 2027

Phase 3Recruiting

Smoking Cessation

NCT07766655

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Phase 3Recruiting

First-Line Treatment

NCT05973786

Clinical

Trials by Indication[1]

Smoking Cessation31 trials

Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation

Completed·—·Phase 3·NCT01406223·282 enrolled

Nicotine Patch Pretreatment for Smoking Cessation in PTSD

Completed·UUS Department of Veterans Affairs·Phase 1·NCT00625131·87 enrolled

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Terminated·—·Phase 2/3·NCT01560507·19 enrolled

Show 28 more trials

Extended Treatment for Smoking Cessation

Completed·SStanford University·Phase 4·NCT01330043·223 enrolled

Bupropion and Weight Control for Smoking Cessation - 1

Completed·UUniversity of Pittsburgh·Phase 4·NCT00006170·349 enrolled

Effect of Smoking Cessation on Tuberculosis Treatment Outcomes

Completed·—·N/A·NCT04848246·292 enrolled

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 1/2·NCT00593099·5 enrolled

Combining Varenicline and Bupropion for Smoking Cessation

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00943618·641 enrolled

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

Completed·HHenry Kranzler·Phase 2·NCT02188459·129 enrolled

Smoking Cessation for People Living With HIV/AIDS

Unknown status·WWayne State University·N/A·NCT01965405·165 enrolled

CPT and Smoking Cessation

Completed·VVA Office of Research and Development·Phase 2/3·NCT01901848·69 enrolled

Bupropion as a Smoking Cessation Aid in Alcoholics

Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 4·NCT00044434·200 enrolled

Concurrent Bupropion / Varenicline for Smoking Cessation

Completed·—·Phase 3·NCT01303861·702 enrolled

Combinations of Pharmacologic Smoking Cessation Treatments

Completed·UUS Department of Veterans Affairs·Phase 1·NCT00018187

Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya

Completed·UUniversity of Maryland, Baltimore·Phase 3·NCT03342027·300 enrolled

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

Unknown status·UUniversity of Minnesota·Phase 2/3·NCT00419731·120 enrolled

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT00332644·1,504 enrolled

Contingency Management for Smoking Cessation in Homeless Smokers

Completed·—·N/A·NCT01789710·25 enrolled

Framing Messages for Smoking Cessation With Bupropion - 6

Completed·YYale University·N/A·NCT00104598·252 enrolled

Impact of Smoking Cessation on Sleep - 5

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 4·NCT00132821·59 enrolled

Bupropion for Hospital-Based Smoking Cessation

Completed·UUniversity of California, San Francisco·Phase 3·NCT00261170·85 enrolled

ISTAPS: A Stepped Primary Care Smoking Cessation Intervention

Unknown status·FFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina·N/A·NCT00125905·3,012 enrolled

Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts

Completed·CCentre for Addiction and Mental Health·Phase 4·NCT01023659·893 enrolled

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

Terminated·YYale University·Phase 4·NCT00511134·4 enrolled

Smoking Cessation Intervention: Effectiveness in Primary Care

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT00296647·1,346 enrolled

Comparative Study of SR Bupropion for Adolescent Smoking Cessation

Unknown status·GGeha Mental Health Center·N/A·NCT00819078·80 enrolled

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

Completed·VVA Office of Research and Development·Phase 4·NCT04135937·12 enrolled

Metabolism-informed Care for Smoking Cessation

Completed·VVanderbilt University Medical Center·N/A·NCT03227679·82 enrolled

Disease Management for Smoking Cessation

Completed·UUniversity of Kansas Medical Center·Phase 3·NCT00440115·750 enrolled

A Randomized, Double-Blind, Placebo and Active-Controlled Trial to Evaluate the Efficacy and Safety of AXS-05 for Smoking Cessation in Adults

Recruiting·AAxsome Therapeutics, Inc.·Phase 3·NCT07766655·705 enrolled

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

Completed·UUniversity of California, San Francisco·Approved·NCT03950427·108 enrolled

Depression10 trials

Lethargic Depression Study

Completed· GSK logo

GSK·Phase 3·NCT00064467·268 enrolled

A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway

Unknown status·PPeking University·Phase 4·NCT03148509·300 enrolled

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

Terminated·NNew York State Psychiatric Institute·Phase 4·NCT00449007·5 enrolled

Show 7 more trials

Assessing Symptomatic Clinical Episodes in Depression

Completed·AAxsome Therapeutics, Inc.·Phase 2·NCT03595579·97 enrolled

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT03993457·18 enrolled

Treatment of Depression Following Multiple Brain Tests

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00296777·28 enrolled

Effects of Bupropion in Depression

Completed·UUniversity of Oxford·N/A·NCT02104128·80 enrolled

Dichotic Listening as a Predictor of Medication Response in Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00404755·17 enrolled

A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults

Withdrawn·NNew York State Psychiatric Institute·Phase 4·NCT01942187

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

Recruiting·MMayo Clinic·Approved·NCT07266545·120 enrolled

Major Depressive Disorder7 trials

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

Completed·TThomas Jefferson University·Phase 4·NCT00234195·25 enrolled

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00351910·494 enrolled

Show 4 more trials

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

Completed·AAxsome Therapeutics, Inc.·Phase 3·NCT02741791·312 enrolled

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

Completed·CChi-Un Pae·Phase 4·NCT01477931·50 enrolled

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

Completed· GSK logo

GSK·Phase 3·NCT02191397·534 enrolled

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·Phase 4·NCT01764867·1,080 enrolled

Treatment6 trials

Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)

Completed·—·N/A·NCT02873754·11 enrolled

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

Completed·UUniversity of Tartu·Phase 4·NCT03927950·135 enrolled

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Recruiting·UUniversity of Kansas Medical Center·Phase 3·NCT05732272·500 enrolled

Show 3 more trials

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

Completed·MMclean Hospital·Phase 4·NCT05537584·133 enrolled

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Completed·JJoseph Valentino, MD·Phase 2·NCT04634071·126 enrolled

Comparing Smoking Treatment Programs for Lighter Smokers - 1

Completed·UUniversity of Pennsylvania·Phase 2·NCT00086411·260 enrolled

Interaction6 trials

Voxelotor CYP and Transporter Cocktail Interaction Study

Completed· Pfizer logo

Pfizer·Phase 1·NCT05981365·44 enrolled

A Drug Interaction Study of Danicopan

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04709094·52 enrolled

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Completed·IInstitut de Recherches Internationales Servier (I.R.I.S.)·Phase 1·NCT07235748·28 enrolled

Show 3 more trials

Drug-drug Interaction Study of KL1333 in Healthy Subjects

Completed·AAbliva AB·Phase 1·NCT04643249·14 enrolled

Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail

Completed·JJules Desmeules·Phase 1·NCT02391688·30 enrolled

Drug-Drug Interaction Study: ASP2151 and Bupropion

Completed·MMaruho Europe Limited·Phase 1·NCT02369172·24 enrolled

78 more indications

Schizophrenia5 trials

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

Completed·—·Phase 4·NCT02420015·35 enrolled

Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia

Completed·SShanghai Mental Health Center·Phase 4·NCT02736474·22 enrolled

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Terminated·TThe University of Texas Health Science Center, Houston·Phase 1·NCT06374290·2 enrolled

Show 2 more trials

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

Terminated·YYale University·Phase 2·NCT03132571·5 enrolled

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

Completed·—·Phase 2·NCT00136760·57 enrolled

Methamphetamine Dependence5 trials

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00135785·73 enrolled

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00687713·200 enrolled

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

Completed·SSan Francisco Department of Public Health·Phase 2·NCT00318409·30 enrolled

Show 2 more trials

Bupropion for the Treatment of Methamphetamine Dependence - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00069251·150 enrolled

Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder

Active, not recruiting·NNational Institute on Drug Abuse (NIDA)·Phase 3·NCT06233799·360 enrolled

Smoking5 trials

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

Completed·YYale University·Phase 2·NCT00580853·62 enrolled

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

Completed·—·Phase 4·NCT02995915·45 enrolled

Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals

Completed·UUniversity of Tennessee·N/A·NCT00308763·594 enrolled

Show 2 more trials

Pharmacogenetics, Emotional Reactivity and Smoking

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT00507728·646 enrolled

CPT-SMART for Treatment of PTSD and Cigarette Smoking

Completed·VVA Office of Research and Development·Approved·NCT03978442·115 enrolled

Mood Disorder3 trials

Integrated Treatment for Cocaine and Mood Disorders - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00227812·140 enrolled

Dynamic Measures of Neurochemistry in Mood Disorders

Completed·VVanderbilt University Medical Center·Phase 4·NCT00178828·42 enrolled

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177567·60 enrolled

Effectiveness3 trials

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Recruiting·NNational Institute of Respiratory Diseases, Mexico·Phase 4·NCT06254001·134 enrolled

Effectiveness of Bupropion in Treating Marijuana Dependent Individuals

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00142870·30 enrolled

Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00249509·132 enrolled

Tics2 trials

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

Completed· Novartis logo

Novartis·Phase 1·NCT01769768·114 enrolled

The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02305901·18 enrolled

Bipolar Disorder2 trials

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Completed·NNational Institute of Mental Health (NIMH)·N/A·NCT00012558·5,000 enrolled

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated·UUniversity of New Mexico··NCT02893371·1,037,352 enrolled

Smokers2 trials

Individualizing Pharmacotherapy for African American Smokers

Completed·UUniversity of Kansas Medical Center·Phase 3·NCT03897439·392 enrolled

Bupropion and Cigarette-Related Cues in Smokers

Completed·UUniversity of California, Los Angeles·Phase 1·NCT03920319·34 enrolled

Binge Drinking2 trials

Buproprion for Binge Drinking

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT03169244·42 enrolled

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT02842073·12 enrolled

Treatment Resistant Depression2 trials

Interpersonal Psychotherapy for Treatment Resistant Depression

Unknown status·HHospital de Clinicas de Porto Alegre·N/A·NCT01896349·74 enrolled

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03852160

Midazolam2 trials

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06367153·18 enrolled

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06973005·16 enrolled

Itching2 trials

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

Completed·RRose Research Center, LLC·Phase 3·NCT04388319·26 enrolled

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

Completed·RRose Research Center, LLC·Phase 3·NCT05205811·180 enrolled

Cocaine Abuse2 trials

Dopamine Reuptake Inhibitors of Cocaine Abuse - 1

Terminated·YYale University·Phase 1·NCT00000276

Cocaine Abuse and Attention Deficit Disorder - 3

Completed·NNational Institute on Drug Abuse (NIDA)·N/A·NCT00000268·32 enrolled

Methamphetamine2 trials

Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

Unknown status·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT00040040·20 enrolled

Study of Medical Treatment for Methamphetamine Addiction

Completed·UUniversity of California, Los Angeles·Phase 2·NCT00833443·84 enrolled

Nicotine Dependence2 trials

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00124683·59 enrolled

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

Completed·UUniversity of Minnesota·Phase 2/3·NCT00749658·121 enrolled

Suicide2 trials

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

Terminated·NNew York State Psychiatric Institute·Phase 4·NCT00429169·101 enrolled

Treatment of Adolescent Suicide Attempters (TASA)

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00080158·120 enrolled

Tobacco Cessation2 trials

The MATCH (Medication Aids for Tobacco Cessation and Health) Study

Completed·CCentre for Addiction and Mental Health·N/A·NCT02146911·968 enrolled

Mobile Contingency Management for Marijuana and Tobacco Cessation

Completed·—·N/A·NCT02869451·7 enrolled

ESS2 trials

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

Completed· GSK logo

GSK·Phase 1·NCT00625859·27 enrolled

PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011

Completed· GSK logo

GSK··NCT02039960·1 enrolled

Drug Interactions2 trials

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

Completed·IIndiana University·Phase 4·NCT02401256·70 enrolled

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

Completed·IIndiana University·Phase 1·NCT03420469·28 enrolled

Acute2 trials

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

Completed·NNew York State Psychiatric Institute·Phase 1·NCT00136747·45 enrolled

The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity

Completed·AAffective Neuroscience Laboratory·Phase 1·NCT00205946·32 enrolled

Single Dose1 trial

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05932277·22 enrolled

Alcohol Dependence1 trial

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 3·NCT00304707·143 enrolled

Depressed1 trial

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

Completed·NNYU Langone Health·Phase 1·NCT00285584·41 enrolled

Substance Use Disorder1 trial

Bupropion for ADHD in Adolescents With Substance Use Disorder

Completed·UUniversity of Colorado, Denver·Phase 4·NCT00936299·105 enrolled

Methadone1 trial

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Unknown status·UUniversity of Washington·Phase 1·NCT00504413·20 enrolled

Metabolism1 trial

The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers

Completed·TTel-Aviv Sourasky Medical Center·N/A·NCT00267813·24 enrolled

Smokeless Tobacco1 trial

Treating Smokeless Tobacco Use in Rural Veterans

Unknown status·MMark Vander Weg·N/A·NCT02994082·123 enrolled

Advanced Solid Tumors1 trial

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT03864042·56 enrolled

Veterans1 trial

Tailored Tobacco Quitline for Rural Veterans

Completed·IIowa City Veterans Affairs Medical Center·Phase 2·NCT01592695·63 enrolled

Prevention1 trial

Pharmacologic Relapse Prevention for Alcoholic Smokers

Completed·MMayo Clinic·Phase 2·NCT00000457·195 enrolled

Oral1 trial

A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03058419·16 enrolled

Cocaine Dependence1 trial

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

Completed·CCraig Rush·Phase 1·NCT01739192·34 enrolled

Overweight1 trial

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06564441·34 enrolled

Binge Eating1 trial

Craving, Binge Eating and Obesity

Completed·YYale University·Phase 2/3·NCT00414167·61 enrolled

Advanced Solid Tumor1 trial

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04457180·18 enrolled

Esketamine1 trial

Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02568176·71 enrolled

Drug1 trial

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04464577

Adult1 trial

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT07223671·32 enrolled

Veteran1 trial

Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers

Completed·VVA Office of Research and Development·Phase 4·NCT02245308·133 enrolled

Adolescent1 trial

Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression

Unknown status·UUma Rao·Phase 4·NCT00106197·130 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking

Terminated·NNational Institute on Drug Abuse (NIDA)·Phase 2/3·NCT00248118·72 enrolled

Electroencephalography1 trial

Electroencephalography (EEG) Signal Processing

Unknown status·SSt. Joseph's Healthcare Hamilton··NCT01369290·150 enrolled

Restless Legs Syndrome1 trial

Bupropion and Restless Legs Syndrome

Completed·—·Phase 2/3·NCT00621517·60 enrolled

First-line Treatment1 trial

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973786·418 enrolled

Malignancy1 trial

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03301207·25 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT04446039·370,212 enrolled

Agitation1 trial

Addressing Dementia Via Agitation-Centered Evaluation

Completed·AAxsome Therapeutics, Inc.·Phase 2/3·NCT03226522·366 enrolled

Age1 trial

Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.

Completed·PParc de Salut Mar·Phase 1·NCT04757532·9 enrolled

Sexual Function1 trial

Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning

Completed·WWeill Medical College of Cornell University·Phase 4·NCT00611975·83 enrolled

Aging1 trial

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Withdrawn·AAlto Neuroscience·Phase 4·NCT04388189

Hemodialysis1 trial

Bupropion for Depression in ESRD Patients on Hemodialysis

Terminated·UUniversity of Arkansas·Phase 4·NCT02238977·1 enrolled

Tobacco Use Cessation1 trial

Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya

Completed·UUniversity of California, San Francisco·Phase 4·NCT05351606·580 enrolled

Stimulant Use Disorder1 trial

Relapse Prevention in Stimulant Use Disorder

Withdrawn·UUniversity of California, Los Angeles·Phase 1·NCT04553263

Relapse1 trial

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

Completed·—·N/A·NCT01990079·15 enrolled

Pathological Gambling1 trial

Bupropion in the Treatment of Pathological Gambling

Completed·UUniversity of Iowa·N/A·NCT00055393·80 enrolled

Maintenance Treatment1 trial

Maintenance Treatment for Abstinent Smokers

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 3·NCT00063323·589 enrolled

Weight Gain1 trial

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

Completed·YYale University·Phase 1/2·NCT00129246·40 enrolled

Small Cell Lung Cancer1 trial

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT01048983

Depressive Symptoms1 trial

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Recruiting·AAxsome Therapeutics, Inc.·Phase 4·NCT06223880·350 enrolled

Transcranial Magnetic Stimulation1 trial

Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT01583023·45 enrolled

Head and Neck Cancer1 trial

Symptom Burden in Head and Neck Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01219673·1 enrolled

Tobacco1 trial

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

Unknown status·MMark Vander Weg·Phase 3·NCT01892813·411 enrolled

Cognitive Function1 trial

Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers

Completed·UUniversity Hospital, Montpellier·N/A·NCT00285155·12 enrolled

Antidepressants1 trial

A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression

Unknown status·YYuqi Cheng·Phase 1·NCT03623711·200 enrolled

Attention Deficit Hyperactivity Disorder1 trial

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00061087·115 enrolled

ALS1 trial

Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Withdrawn·NNew York State Psychiatric Institute·Phase 4·NCT03278938

Apathy1 trial

Apathy Cure Through Bupropion in Huntington's Disease

Completed·—·Phase 2·NCT01914965·40 enrolled

Imaging1 trial

PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration

Completed·SSeoul National University Hospital·Phase 4·NCT00846339·12 enrolled

Cigarette Smoker1 trial

A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.

Unknown status·HHadassah Medical Organization·N/A·NCT00396669·24 enrolled

Cardiometabolic Syndrome1 trial

A 52-week Multicenter, Randomized, Parallel-group Trial in Overweight People Investigating Lifestyle Changes, Mushroom Supplementation and Bupropion to Reduce Adiposity and Cardiometabolic Risk

Not yet recruiting·UUppsala University·Phase 3·NCT07806279·250 enrolled

Breast Cancer1 trial

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

Recruiting· Roche logo

Roche·Phase 3·NCT05646862·420 enrolled

Early-stage Breast Cancer1 trial

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

Not yet recruiting·UUniversity of Illinois at Chicago·Preclinical·NCT07596212·100 enrolled

Chronic Kidney Diseases1 trial

Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)

Active, not recruiting·SStony Brook University·Phase 2·NCT04422652·201 enrolled

Postpartum1 trial

Bupropion for the Prevention of Postpartum Smoking Relapse

Completed·UUniversity of Minnesota·Approved·NCT04098874·161 enrolled

Lactating Women on Select DOI1 trial

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting·DDuke University··NCT03511118·1,600 enrolled

Tobacco Use Disorder1 trial

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

Not yet recruiting·VVA Office of Research and Development·Preclinical·NCT07714200·120 enrolled

Pancreatitis, Chronic1 trial

Smoking Cessation Treatment Escalation Among Patients With Recurrent Acute Pancreatitis and Chronic Pancreatitis

Withdrawn·MMayo Clinic·Phase 2·NCT07171112

Unspecified4 trials

Influence of Bupropion on the Effects of MDMA

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT01771874·16 enrolled

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

A Phase 1, 3-Part Study to Evaluate the Effect of CYP3A4 Inhibition and Induction on the Pharmacokinetics of Clemizole and the Effect of Clemizole on the Pharmacokinetics of CYP2C19, CYP3A4, and CYP2B6 Substrates in Healthy Participants

Completed·EEpygenix·Phase 1·NCT07824193·54 enrolled

Show 1 more trial

A Phase 1, Single-Center, Repeat-Dose, Open-Label, Fixed-Sequence Drug-Drug Interaction Study of ZX008 in Healthy Male Or Female Study Participants 18 To 55 Years Of Age

Completed· UCB logo

UCB·Phase 1·NCT06679413·22 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 30, 1985

WELLBUTRIN

NDA NDA018644

Oct 4, 1996

WELLBUTRIN SR

NDA NDA020358

Oct 4, 1996

WELLBUTRIN SR

NDA NDA020358

May 14, 1997

ZYBAN

NDA NDA020711

Dec 16, 1997

WELLBUTRIN SR

NDA NDA020358

Nov 30, 1998

WELLBUTRIN SR

NDA NDA020358

Nov 30, 1998

WELLBUTRIN SR

NDA NDA020358

Nov 30, 1998

WELLBUTRIN SR

NDA NDA020358

Jan 26, 1999

WELLBUTRIN SR

NDA NDA020358

Apr 6, 1999

WELLBUTRIN SR

NDA NDA020358

Apr 6, 1999

WELLBUTRIN SR

NDA NDA020358

Apr 6, 1999

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Apr 10, 2000

WELLBUTRIN SR

NDA NDA020358

Aug 4, 2000

WELLBUTRIN SR

NDA NDA020358

Oct 11, 2000

WELLBUTRIN SR

NDA NDA020358

Oct 11, 2000

WELLBUTRIN SR

NDA NDA020358

Oct 11, 2000

WELLBUTRIN SR

NDA NDA020358

Jun 11, 2001

WELLBUTRIN SR

NDA NDA020358

Feb 13, 2002

WELLBUTRIN SR

NDA NDA020358

Jun 14, 2002

WELLBUTRIN SR

NDA NDA020358

Jun 20, 2002

WELLBUTRIN SR

NDA NDA020358

Jun 20, 2002

WELLBUTRIN SR

NDA NDA020358

Jul 12, 2002

WELLBUTRIN SR

NDA NDA020358

Jul 12, 2002

WELLBUTRIN SR

NDA NDA020358

Oct 2, 2002

WELLBUTRIN SR

NDA NDA020358

Oct 22, 2002

WELLBUTRIN SR

NDA NDA020358

Aug 28, 2003

WELLBUTRIN XL

NDA NDA021515

Aug 28, 2003

WELLBUTRIN XL

NDA NDA021515

Apr 26, 2004

WELLBUTRIN SR

NDA NDA020358

May 27, 2004

WELLBUTRIN XL

NDA NDA021515

May 27, 2004

WELLBUTRIN SR

NDA NDA020358

Oct 28, 2004

WELLBUTRIN XL

NDA NDA021515

Jan 12, 2005

WELLBUTRIN XL

NDA NDA021515

Jan 12, 2005

WELLBUTRIN SR

NDA NDA020358

Feb 28, 2006

WELLBUTRIN SR

NDA NDA020358

Feb 28, 2006

WELLBUTRIN XL

NDA NDA021515

Jun 12, 2006

WELLBUTRIN XL

NDA NDA021515

Jun 12, 2006

WELLBUTRIN XL

NDA NDA021515

Jul 3, 2006

WELLBUTRIN SR

NDA NDA020358

Jul 3, 2006

WELLBUTRIN SR

NDA NDA020358

Jul 3, 2006

WELLBUTRIN XL

NDA NDA021515

Jan 29, 2007

WELLBUTRIN SR

NDA NDA020358

Aug 2, 2007

WELLBUTRIN XL

NDA NDA021515

Aug 2, 2007

WELLBUTRIN SR

NDA NDA020358

Apr 23, 2008

APLENZIN

NDA NDA022108

Jul 1, 2009

WELLBUTRIN XL

NDA NDA021515

Jul 1, 2009

WELLBUTRIN SR

NDA NDA020358

Jul 1, 2009

WELLBUTRIN SR

NDA NDA020358

Jul 1, 2009

WELLBUTRIN XL

NDA NDA021515

Feb 26, 2010

WELLBUTRIN XL

NDA NDA021515

Feb 26, 2010

WELLBUTRIN SR

NDA NDA020358

May 25, 2010

WELLBUTRIN SR

NDA NDA020358

May 25, 2010

WELLBUTRIN XL

NDA NDA021515

May 17, 2011

WELLBUTRIN SR

NDA NDA020358

May 17, 2011

WELLBUTRIN SR

NDA NDA020358

Jul 25, 2011

WELLBUTRIN SR

NDA NDA020358

Jul 26, 2011

WELLBUTRIN XL

NDA NDA021515

Jul 26, 2011

WELLBUTRIN XL

NDA NDA021515

Nov 10, 2011

FORFIVO XL

NDA NDA022497

Aug 2, 2012

WELLBUTRIN XL

NDA NDA021515

Aug 2, 2012

WELLBUTRIN SR

NDA NDA020358

Mar 19, 2013

WELLBUTRIN SR

NDA NDA020358

Dec 23, 2013

WELLBUTRIN SR

NDA NDA020358

Dec 23, 2013

WELLBUTRIN SR

NDA NDA020358

Jul 11, 2014

WELLBUTRIN XL

NDA NDA021515

Jul 17, 2014

WELLBUTRIN SR

NDA NDA020358

Nov 21, 2014

WELLBUTRIN XL

NDA NDA021515

Dec 16, 2014

WELLBUTRIN SR

NDA NDA020358

Dec 30, 2014

WELLBUTRIN XL

NDA NDA021515

Dec 30, 2014

WELLBUTRIN XL

NDA NDA021515

Apr 25, 2016

WELLBUTRIN SR

NDA NDA020358

May 24, 2016

WELLBUTRIN XL

NDA NDA021515

Aug 30, 2016

WELLBUTRIN XL

NDA NDA021515

May 4, 2017

WELLBUTRIN SR

NDA NDA020358

May 4, 2017

WELLBUTRIN XL

NDA NDA021515

May 10, 2017

WELLBUTRIN SR

NDA NDA020358

Aug 11, 2017

WELLBUTRIN SR

NDA NDA020358

Nov 5, 2019

WELLBUTRIN SR

NDA NDA020358

Nov 5, 2019

WELLBUTRIN XL

NDA NDA021515

Oct 20, 2020

WELLBUTRIN SR

NDA NDA020358

Jul 8, 2021

WELLBUTRIN XL

NDA NDA021515

Mar 4, 2022

WELLBUTRIN XL

NDA NDA021515

Dec 6, 2022

WELLBUTRIN SR

NDA NDA020358

May 7, 2024

WELLBUTRIN SR

NDA NDA020358

May 7, 2024

WELLBUTRIN XL

NDA NDA021515

Nov 5, 2025

WELLBUTRIN SR

NDA NDA020358

Nov 5, 2025

WELLBUTRIN XL

NDA NDA021515

Sources

References

[1]
ClinicalTrials.gov — 172 trial records for Bupropion. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Wellbutrin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Bupropion compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Bupropion. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020358). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Wellbutrin. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Dopamine Transporter Inhibitor; Norepinephrine Transporter Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Patent Landscape[6]

Patent Cliff

Aug 23, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7569610Jun 27, 2026

7241805Jun 27, 2026

7645802Jun 27, 2026

7572935Jun 27, 2026

7649019Jun 27, 2026

4 more patents

7585897Jun 27, 2026

7662407Jun 27, 2026

7671094Jun 27, 2026

7674479Aug 23, 2028